Drug intelligence / Profile preview

Investigational Influenza Vaccine 1

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Injection

Overview

Investigational Influenza Vaccine 1 is an mRNA-based vaccine developed by ModernaTX, Inc. It is administered as a sterile liquid for injection and is being evaluated in a Phase 1/2 clinical trial for its safety, reactogenicity, and immunogenicity against influenza.

Other names: Investigational Influenza Vaccine 1

Beyond the preview

Go deeper on Investigational Influenza Vaccine 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Investigational Influenza Vaccine 1.

Explore the full profile